Tafasitamab Plus Lenalidomide Shows Manageable Safety Profile in R/R DLBCL
Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab (Monjuvi) combined with lenalidomide (Revlimid) for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.
According to Salles, 50% of patients experienced a drop in white blood cell count and 1/3 of patients required an injection to boost count. Additionally, 1 in 6 patients experienced infection that may led to hospitalization. Most of these infections were common, however some lead to hospitalization. No instances of septic shock were reported.
Anemia occurred in 1/3 of patients. Patients also experienced platelet cell diminishment. One in 6 patients required treatment for these adverse events.
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL
August 15th 2024During an in-person Community Case Forum event, Hayder Saeed, MD, discussed the RE-MIND2 matched cohort data and real-world data on the combination of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.
Read More
Takeaways on Tolerability Challenges With Loncastuximab in DLBCL
July 30th 2024During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the study design of the LOTIS-2 trial and adverse events related to loncastuximab tesirine in diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab/Chemo Leads to Survival Benefit in Transplant-Ineligible R/R DLBCL
July 3rd 2024A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.
Read More
